



THE NOVELTY STUDY

Identifying new dimensions in respiratory disease

NOVELTY: Reframing obstructive lung disease by enabling the move towards a preventive and precision medicine-led clinical paradigm

Extension study now underway

NOVELTYstudy.com

NOVELTY study¹

~12,000 patients with asthma and/or COPD	19 countries	~350 sites; ~50% of patients from primary care	3-year follow-up; completion May 2021

Subset of NOVELTY patients completing 3 years of follow-up (~3,000 patients planned)

SCIENTIFIC RATIONALE

Extended follow-up to allow evaluation of **disease trajectories**, including lung function, HRQoL and exacerbations, and examine their associations with patient **phenotypes** and **endotypes**

Extension study – completion May 2023

Year 1, 2, 3 Annual visits to clinical practice

PATIENT SURVEY

COVID-19 & early respiratory events


EXTENSION VISIT TO CLINICAL PRACTICE

- Physiology/symptoms
- COVID-19 infection/vaccination
- Medication
- Healthcare resource use
- Patient-reported outcomes
- Haematology
- Spirometry

PATIENT SURVEY

END OF EXTENSION STUDY

Patients at ~90 sites in 11 countries



AIMS




Further understand **longer-term disease trajectories** and **outcomes**, relative to early life events



Generate results **comparable with other long-term studies**



Explore major criteria by which **physicians classify** disease severity and how **patients perceive** their disease severity



Assess the impact of **COVID-19** on disease burden and progression, as well as patient behaviours

COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; HRQoL, health-related quality of life
NOVELTY, NOVEL observational longiTudinal studY.

¹Reddel HK et al. ERJ Open Res 2019;5:00036–2018

Veeva ID: Z4-40139; date of preparation: March 2022; date of expiry: March 2024